Malaysia faces a mounting public health challenge as cardio-renal-metabolic diseases—conditions affecting the heart, kidneys and metabolism—become increasingly prevalent among its population. The National Cancer Society Malaysia has issued an urgent call for a coordinated national screening strategy to detect and manage these interlinked health conditions more effectively, emphasizing that current fragmented approaches are failing to prevent serious complications.
The scale of the problem is substantial. Recent screening data from the NCSM-Boehringer Ingelheim Saring@Komuniti Project revealed that among 5,000 individuals from underserved communities in the Klang Valley, nearly nine out of every ten people carried two or more risk factors for these diseases. The findings underscore a hidden epidemic of metabolic dysfunction across the country, with disease burden concentrated among vulnerable populations that often lack regular access to comprehensive health monitoring.
The screening initiative, conducted with support from the Ministry of Health, documented concerning prevalence rates that signal systematic failures in early detection. Among participants, 41.3 per cent were classified as obese while another 28.8 per cent were overweight, together accounting for seven out of every ten individuals struggling with unhealthy body weight. More alarming were the blood sugar abnormalities discovered: 34.5 per cent had pre-diabetes and 35.1 per cent had existing diabetes, indicating that more than two-thirds of screened individuals faced significant metabolic dysfunction requiring intervention.
These conditions are particularly dangerous because they frequently develop simultaneously and reinforce each other's progression. Heart disease, kidney disease and diabetes share common underlying risk factors such as hypertension, obesity and poor metabolic control. When present together, each disease accelerates the others, creating a cascade of declining health. The interconnected nature of these conditions means that identifying one disease should trigger screening for the others—a logic that current healthcare systems have largely failed to implement.
National health statistics illustrate the accelerating burden. Chronic kidney disease prevalence has risen dramatically from 9.1 per cent in 2011 to 15.5 per cent in 2019, representing a seventy percent increase in less than a decade. Meanwhile, the number of Malaysians requiring dialysis—the most intensive form of kidney disease treatment—has more than tripled over the past twenty years, placing enormous strain on healthcare infrastructure and imposing devastating costs on patients and families. These trends suggest that prevention efforts have proven insufficient to slow disease progression.
The policy briefs released by NCSM identify a fundamental structural problem: existing healthcare systems typically address diseases in isolation rather than recognizing their interconnected nature. A patient presenting with high blood pressure might receive treatment for hypertension alone, without comprehensive screening for underlying kidney disease or metabolic dysfunction. This siloed approach creates missed opportunities for early intervention and allows serious conditions to advance undetected until they become difficult and expensive to manage.
Equally problematic are gaps in care continuity after initial screening. Fragmented referral pathways mean that individuals identified as at-risk through screening may not successfully transition to diagnosis and treatment. Inconsistent follow-up systems and barriers to accessing specialist care prevent patients from receiving timely intervention following abnormal results. These systemic failures effectively nullify the benefits of screening itself, leaving patients aware of their risks but unable to access appropriate management.
To address these challenges, NCSM's policy briefs recommend several concrete actions. Scaling up cardio-renal-metabolic co-screening programmes nationwide would ensure systematic detection of interconnected diseases across all communities. Embedding standardized risk assessments into routine health checks at primary care clinics would make screening accessible without requiring additional specialist appointments. Strengthening referral mechanisms and establishing consistent follow-up systems would ensure that positive findings lead to actual treatment rather than remaining unaddressed.
Dr Murallitharan Munisamy, Managing Director of NCSM, emphasized that Malaysia has an opportunity to fundamentally transform its approach to chronic disease management. Rather than treating cardiovascular, kidney and metabolic health as separate domains, the health system should recognize and address them as components of an integrated continuum. Early detection becomes meaningful only when matched by coordinated follow-up, timely diagnosis and sustained long-term management. Without such integration, screening merely identifies problems without solving them.
The timing of this advocacy is significant given Malaysia's trajectory of rising chronic disease rates. The healthcare system faces mounting pressure from an aging population and increasing prevalence of lifestyle-related diseases. Without proactive intervention through improved screening and management, healthcare costs will continue escalating while patient outcomes deteriorate. The burden will fall heaviest on lower-income communities that already struggle to access advanced medical care.
Boehringer Ingelheim, which collaborated with NCSM on the screening project, acknowledged that cardiovascular, kidney and metabolic conditions represent a connected health challenge requiring integrated solutions. The pharmaceutical industry's involvement in developing policy recommendations alongside civil society and government reflects growing recognition that addressing these conditions demands coordinated action across multiple sectors.
Implementing a national co-screening strategy would require investment in healthcare infrastructure, training of primary care providers in integrated assessment protocols, and development of coordinated referral systems linking primary, secondary and tertiary care. The upfront costs, however, would likely prove far less than the mounting expenses of treating advanced disease, dialysis and cardiovascular complications. For Malaysian policymakers, the evidence suggests that shifting toward integrated cardio-renal-metabolic screening represents not merely a health improvement but an economic imperative.
